$Immix Biopharma (IMMX.US)$ NEWS Immix Biopharma Announces L...
NEWS
Immix Biopharma Announces Late-Breaking NXC-201 Clinical Data Abstract Accepted for Oral Presentation at the 27th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT)
LOS ANGELES, April 15, 2024 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (Nasdaq: IMMX) (“ImmixBio”, “Company”, “We” or “Us” or “IMMX”), a clinical-stage biopharmaceutical company trailblazing cell therapies in AL Amyloidosis and other autoimmune diseases, today announced that updated NXC-201 clinical data has been selected for presentation at the upcoming 27th Annual Meeting of The American Society of Gene & Cell Therapy (ASGCT) to be held in Baltimore May 7-11, 2024.
“We are delighted to present continued clinical progress developing what we believe is the only CAR-T in AL Amyloidosis at the upcoming 27thAnnual Meeting of The American Society of Gene & Cell Therapy,” said Polina Stepensky, M.D., Director of the Hadassah Medical Organization’s Department of Bone Marrow Transplantation and Immunotherapy for Adults and Children, and principal study investigator for the NEXICART-1 Phase 1b/2a clinical trial of NXC-201. “A potential one-time treatment such as CAR-T NXC-201 for relapsed/refractory AL amyloidosis patients would be a welcome option for this devastating disease.”
Oral Presentation:
Title: “Academic BCMA-CART cells (HBI0101), a promising approach for the treatment of LC Amyloidosis”
Oral Presentation Date/Time: Friday May 10, 2024 8:45 am - 9:00am Eastern Time
Event: 27th Annual Meeting of The American Society of Gene and Cell Therapy, Baltimore, MD
Session Title: Late-Breaking Abstracts II
Location: Baltimore Convention Center, Baltimore, MD
“We are delighted to present continued clinical progress developing what we believe is the only CAR-T in AL Amyloidosis at the upcoming 27thAnnual Meeting of The American Society of Gene & Cell Therapy,” said Polina Stepensky, M.D., Director of the Hadassah Medical Organization’s Department of Bone Marrow Transplantation and Immunotherapy for Adults and Children, and principal study investigator for the NEXICART-1 Phase 1b/2a clinical trial of NXC-201. “A potential one-time treatment such as CAR-T NXC-201 for relapsed/refractory AL amyloidosis patients would be a welcome option for this devastating disease.”
Oral Presentation:
Title: “Academic BCMA-CART cells (HBI0101), a promising approach for the treatment of LC Amyloidosis”
Oral Presentation Date/Time: Friday May 10, 2024 8:45 am - 9:00am Eastern Time
Event: 27th Annual Meeting of The American Society of Gene and Cell Therapy, Baltimore, MD
Session Title: Late-Breaking Abstracts II
Location: Baltimore Convention Center, Baltimore, MD
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
Spread kindness and love. Life is short. Don’t let greed eat you.
420Followers
64Following
2713Visitors
Follow